Travere Therapeutics

Yahoo Finance • 8 days ago

Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Continue Reading View Comments... Full story

Yahoo Finance • 8 days ago

Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Continue Reading View Comments... Full story

Yahoo Finance • 16 days ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • last month

Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M

Earnings Call Insights: Travere Therapeutics (TVTX) Q3 2025 MANAGEMENT VIEW * President and CEO Eric Dube emphasized "exceptional progress across our three key priorities: delivering strong commercial execution in IgA nephropathy, prep... Full story

Yahoo Finance • last month

Mid-America Apartment Communities' Series A Preferred Shares Crosses Above 7.5% Yield Territory

In trading on Tuesday, shares of Mid-America Apartment Communities Inc's 8 1/2% Series A Cumulative Redeemable Preferred Shares (Symbol: MAA.PRI) were yielding above the 7.5% mark based on its quarterly dividend (annualized to $4.25), with... Full story

Yahoo Finance • 2 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, October 10, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate o... Full story

Yahoo Finance • 3 months ago

Target initiated, Nike upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Out... Full story

Yahoo Finance • 3 months ago

Implied FYX Analyst Target Price: $122

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside

We recently published AI Frenzy: 10 Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on Wednesday. Travere Therapeutics, Inc. (NASDAQ:TVTX) soared to a new all-time... Full story

Yahoo Finance • 3 months ago

Notable Wednesday Option Activity: MCD, DAKT, TVTX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in McDonald's Corp (Symbol: MCD), where a total of 16,370 contracts have traded so far, representing approximately 1.6 million underl... Full story

Yahoo Finance • 4 months ago

Notable Wednesday Option Activity: TVTX, EL, SMR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Travere Therapeutics Inc (Symbol: TVTX), where a total volume of 8,102 contracts has been traded thus far today, a contra... Full story

Yahoo Finance • 4 months ago

Travere Therapeutics price target raised to $32 from $30 at Wedbush

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the shares. The firm notes Q2 update represented another strong showing for Filspari with Travere reporting a Filspari... Full story

Yahoo Finance • 4 months ago

Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss

Travere Therapeutics Inc (NASDAQ:TVTX [https://www.chartmill.com/stock/quote/TVTX]) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction. The company posted revenue of $114... Full story

Yahoo Finance • 5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

The U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Nasdaq Composite. In this environment, id... Full story

Yahoo Finance • 5 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton a... Full story

Yahoo Finance • 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton a... Full story

Yahoo Finance • 6 months ago

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTE... Full story

Yahoo Finance • 7 months ago

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products fo... Full story

Yahoo Finance • 9 months ago

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney... Full story